Afamelanotide and Vitamin D in EPP: Research Brief
Patients living with erythropoietic protoporphyria experience severe, lifelong photosensitivity that forces them to avoid sun exposure. Because sunlight is a primary driver of cutaneous vitamin D synthesis, extreme light avoidance frequently puts these individuals at risk for deficiency and poor bone health. In a 2024 paper published in The British journal of dermatology, European researchers evaluated whether medical therapy with afamelanotide alters circulating vitamin D levels in this vulnerable group.
The Sunlight Dilemma in Erythropoietic Protoporphyria
Erythropoietic protoporphyria, commonly abbreviated as EPP, causes painful phototoxic reactions upon exposure to visible light and sunlight. To prevent debilitating pain, individuals diagnosed with the condition must adopt strict sun-avoidance habits. Over years of minimal sunlight exposure, this behavior creates secondary nutritional challenges. Prior research highlighted by the study authors noted that vitamin D deficiency and a high prevalence of osteoporosis are frequent complications among patients with EPP.
In 2016, an approved systemic treatment became available: afamelanotide, a synthetic alpha-melanocyte stimulating hormone analogue designed to increase photoprotection. For more information on the history and medical use of this pharmaceutical implant, see our overview of afamelanotide and medical melanocortins. Because afamelanotide improves light tolerance, questions emerged regarding whether receiving the implant would indirectly or directly improve vitamin D status. Until this investigation, studies evaluating vitamin D in EPP had examined only patients who were not receiving afamelanotide.
Study Design and Patient Cohort
The investigation was designed as a multicentre observational cohort study. Investigators reviewed long-term medical records collected between 2005 and 2021 across two specialized academic hospitals: Erasmus Medical Centre in the Netherlands and University Hospital Düsseldorf in Germany.
To analyze the impact of medical care over time, the researchers gathered routinely collected laboratory data from 230 adult patients with EPP, comprising a total of 1774 vitamin D measurements. The research team categorized patient exposure across four specific clinical treatment states:
- Untreated baseline periods
- Cholecalciferol supplementation alone
- Afamelanotide implant therapy alone
- Combined treatment utilizing both cholecalciferol and afamelanotide
To assess changes while accounting for repeated tests per individual across several years, the authors applied a linear mixed model for longitudinal data, comparing each intervention category against the untreated group.
Key Findings: Afamelanotide Did Not Raise Vitamin D
The data demonstrated that insufficient vitamin D remained widespread among these patients. Routine laboratory values revealed that vitamin D deficiency (defined in the study as levels below 50 nmol L-1) occurred in 71.8% of patients. Severe deficiency (defined as levels below 30 nmol L-1) occurred in 48.1% of patients.
When measuring the direct relationship between treatments and blood levels, the statistical model showed distinct differences between groups:
- Afamelanotide alone: Did not lead to a significant average increase in vitamin D levels (beta = 0.5).
- Cholecalciferol alone: Produced a statistically significant increase in vitamin D levels (beta = 11.6).
- Combined treatment: Also resulted in a statistically significant increase in vitamin D levels (beta = 15.2).
As documented in the multicentre cohort study report on PubMed, afamelanotide by itself had no measurable effect on circulating vitamin D concentrations.
Study Limitations and Scientific Context
When reviewing these results, readers should keep several methodological factors in mind. First, this represents a single observational cohort study rather than a prospective, randomized controlled trial. It relied on routinely collected clinical registry data gathered between 2005 and 2021, which means testing schedules and lifestyle behaviors were monitored observationally rather than assigned under rigid laboratory controls.
Second, the findings apply specifically to adults diagnosed with EPP, a metabolic disorder characterized by extreme phototoxicity. These findings cannot be generalized to individuals with normal light tolerance or different medical backgrounds. Readers can learn more about how light interacts with cutaneous synthesis in our guide to vitamin D and sun exposure.
Finally, afamelanotide is an authorized prescription medicine administered under direct medical supervision. It should never be confused with unapproved, unregulated synthetic peptide products, such as melanotan I or melanotan II, which are sold illegally online and carry unverified ingredients and significant health hazards. Anyone managing photosensitivity, unusual reactions to UV light, or suspected nutritional deficiencies should always seek evaluation from a qualified physician or dermatologist.
Takeaways for Patient Care
The authors concluded that oral cholecalciferol remains essential for the management of vitamin D deficiency in patients with EPP, regardless of whether they have access to newer therapies like afamelanotide. Because the implant does not elevate serum levels on its own, the researchers suggested that future medical guidelines incorporate regular, continuous monitoring of vitamin D alongside a routine prescription for cholecalciferol for all patients with EPP.
Sources
The effects of cholecalciferol and afamelanotide on vitamin D levels in erythropoietic protoporphyria: a multicentre cohort study. — PubMed (The British journal of dermatology, 2024)
Published October 28, 2026. Sources are linked in the text. See our Medical Disclaimer.